19 May 2020 - As the chief executive of Phlow, the new company awarded $354 million by the federal government this week to make generics that are in short supply during the pandemic, Eric Edwards maintains his business is a public benefit corporation.

Besides generating a profit, Phlow is supposed to serve a greater good.

But in his last role in the pharmaceutical industry, Edwards fell short of benefiting the public, at least according to a U.S. Senate subcommittee report released in 2018. Kaleo, a company Edwards founded with his twin brother, jacked up the price of its Evzio opioid overdose antidote by more than 600% between 2014 and 2017, which cost U.S. taxpayers more than $142 million.

Read Stat News article